Abstract 802P
Background
Maintenance treatment with olaparib has demonstrated significant improvements in median progression-free survival (PFS) compared with placebo in patients with platinum-sensitive relapsed ovarian cancer (PSROC) who are in response to platinum-based chemotherapy (PBC). Olaparib was the first-in-class poly (ADP-ribose) polymerase inhibitor (PARPi) approved as monotherapy in the EU in 12/2014 (hard capsules, HC, 400 mg twice daily) in BRCA-mutated (BRCAm) PSROC. In addition, film-coated tablets (FT, 300 mg, twice daily) were approved in 05/2018 in PSROC regardless of BRCA status. After entering routine clinical practice, real-world data on olaparib were limited and this non-interventional study (NIS) was initiated. Here, final survival results are reported.
Methods
The prospective NIS C-PATROL (NCT02503436) was performed at 68 sites (50 hospitals, 18 office-based) in Germany. Routine clinical data were collected of BRCAm PSROC patients treated with olaparib according to label.
Results
Between 28 Oct 2015 and 30 Sep 2019, 282 patients were enrolled. Of these, 269 patients were included in the analysis (median age: 60 yrs; ECOG ≤1: 93%; ≥2 relapses: 32%; ≥3 prior PBC: 34%). 46 patients started with FT and 223 patients with HC; 70 patients switched from HC to FT. Median follow-up was 23.5 months (range 0.00 – 80.5) and median olaparib treatment duration was 13.6 months (0.1–80.9). 10% of patients received olaparib for ≥5 years. Median PFS was 14.3 months (95% CI 12.2–18.0). Median overall survival was 35.4 months (95% CI 29.2–47.1). 132 patients received at least one subsequent medication. Adverse events (AEs) were consistent with known tolerability profile of olaparib. 31 patients (11.3%, safety set: total n=274) discontinued olaparib treatment and 60 patients (21.9%) received reduced olaparib dose due to AEs.
Conclusions
This real-word study supports efficacy and tolerability of olaparib maintenance therapy after PBC in patients with BRCAm PSROC. Long-term exposure to olaparib was observed with no new safety signals.
Clinical trial identification
NCT02503436.
Editorial acknowledgement
Medical writing assistance was provided by Dr. Yvonne Holighaus and Dr. Katharina Bakhaus, Alcedis GmbH, Giessen, funded by AstraZeneca.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
F. Marmé: Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK/Tesaro, Clovis, Pfizer, Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Novartis, Roche, Gilead/immunomedics, EISAI, PharmaMar, GenomicHealth, Myriad, Seagen; Financial Interests, Institutional, Invited Speaker: Seagen, Daiichi Sankyo, GSK, AstraZeneca; Financial Interests, Institutional, Advisory Board: Roche, Immunicom; Financial Interests, Institutional, Local PI: Roche, Novartis, Eisai, MSD, Vaccibody, GSK; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Roche, Gilead/Immunomedics, German Breast Group, AGO Research GmbH; Financial Interests, Institutional, Funding: AstraZeneca, Lilly, Seagen. F. Hilpert: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, MSD, PharmaMar; Financial Interests, Personal, Other, Honoraria: AstraZeneca, Roche, MSD, PharmaMar, Pfizer, Novartis. M. Welslau: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Bristol Myers Squibb, Celgene, GILEAD, HEXAL, AMGEN, Janssen, Lilly, Novartis, Roche, Astellas, Sanofi. J.P. Grabowski: Financial Interests, Institutional, Speaker, Consultant, Advisor: AstraZeneca, Tesaro/GSK, Clovis, Roche, Amgen, MSD, Pfizer, Riemser, Eisai. A. Schneeweiss: Financial Interests, Institutional, Research Grant: Celgene, Roche, AbbVie; Financial Interests, Personal, Other, Travel expenses: Celgene, Roche; Financial Interests, Personal, Other, Honoraria: Celgene, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly, Seagen, Gilead, GSK, Bayer, Amgen, Pierre Fabre, Roche; Financial Interests, Personal, Other, Travel Expenses: AstraZeneca, Pfizer. A.D. Hartkopf: Financial Interests, Personal, Other, Honoraria: AstraZeneca, GSK, MSD, Clovis, Miltenyi, Roche. I. Runnebaum: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, GSK, PharmaMar, Clovis, Roche, Tesaro; Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, PharmaMar, Fa. Martin, Tuttlingen, Fa. Caresyntax, Clovis, Tesaro, Roche; Financial Interests, Institutional, Coordinating PI: PharmaMar. P. Fasching: Financial Interests, Personal, Advisory Board: Roche, Novartis, Pfizer, Daiichi Sankyo, Eisai, Merck, Sharp & Dohme, AstraZeneca, Hexal, Lilly, Pierre Fabre, Seagen, Agendia, Sanofi Aventis; Financial Interests, Personal, Invited Speaker: Novartis, Daiichi Sankyo, Eisai, Merck, Sharp & Dohme, AstraZeneca, Lilly, Seagen, Gilead; Financial Interests, Personal, Other, Medical Writing Support: Roche; Financial Interests, Institutional, Local PI: BionTech, Cepheid; Non-Financial Interests, Member: ASCO, Arbeitsgemeinschaft für Gynäkologische Onkologie e.V., Translational Research in Oncology, Deutsche Gesellschaft für Senologie e.v. R. Glowik: Other, Personal, Sponsor/Funding, employee of AstraZeneca: AstraZeneca. J. Sehouli: Financial Interests, Institutional, Research Grant: GSK, Clovis, AstraZeneca, Roche, Bayer; Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, AstraZeneca, Clovis, Roche, GSK, Tesaro, Novocure, PharmaMar, Eisai, Bayer, Merck. All other authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11